Immatics (IMTX) Competitors $5.01 +0.01 (+0.20%) Closing price 04:00 PM EasternExtended Trading$5.01 +0.00 (+0.10%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. MTSR, SDGR, DNLI, MIRM, TARS, GMTX, BEAM, NAMS, KYMR, and BLTEShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Metsera (MTSR), Schrödinger (SDGR), Denali Therapeutics (DNLI), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Metsera Schrödinger Denali Therapeutics Mirum Pharmaceuticals Tarsus Pharmaceuticals Gemini Therapeutics Beam Therapeutics NewAmsterdam Pharma Kymera Therapeutics Belite Bio Immatics (NASDAQ:IMTX) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Does the media favor IMTX or MTSR? In the previous week, Metsera had 3 more articles in the media than Immatics. MarketBeat recorded 5 mentions for Metsera and 2 mentions for Immatics. Immatics' average media sentiment score of 1.73 beat Metsera's score of 0.72 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Metsera 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IMTX or MTSR? Immatics presently has a consensus price target of $16.67, suggesting a potential upside of 233.00%. Metsera has a consensus price target of $47.00, suggesting a potential upside of 100.43%. Given Immatics' stronger consensus rating and higher probable upside, research analysts plainly believe Immatics is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMTX or MTSR more profitable? Metsera has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Metsera's return on equity of 0.00% beat Immatics' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-47.94% -15.90% -9.38% Metsera N/A N/A N/A Which has better valuation & earnings, IMTX or MTSR? Metsera has lower revenue, but higher earnings than Immatics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$155.84M3.90-$104.98M$0.1435.75MetseraN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of IMTX or MTSR? 64.4% of Immatics shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer IMTX or MTSR? Immatics received 27 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 75.61% of users gave Immatics an outperform vote. CompanyUnderperformOutperformImmaticsOutperform Votes3175.61% Underperform Votes1024.39% MetseraOutperform Votes4100.00% Underperform VotesNo Votes SummaryImmatics beats Metsera on 8 of the 13 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$608.36M$2.96B$5.49B$7.95BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-7.5830.2822.6218.58Price / Sales3.90496.13397.85103.49Price / CashN/A168.6838.1834.62Price / Book1.743.176.744.25Net Income-$104.98M-$72.35M$3.22B$248.18M7 Day Performance7.17%0.96%1.59%1.36%1 Month Performance25.13%8.29%4.09%3.85%1 Year Performance-53.70%-22.57%15.98%5.37% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.0574 of 5 stars$5.01+0.2%$16.67+232.7%-49.6%$608.97M$155.84M-7.59260Positive NewsMTSRMetseraN/A$19.51-0.3%$47.00+140.9%N/A$2.05BN/A0.0081News CoverageHigh Trading VolumeSDGRSchrödinger2.273 of 5 stars$26.19+1.7%$33.00+26.0%+5.1%$1.91B$207.54M-11.19790Upcoming EarningsDNLIDenali Therapeutics4.1611 of 5 stars$13.15+3.2%$37.57+185.7%+7.8%$1.91B$330.53M-4.76430Upcoming EarningsPositive NewsMIRMMirum Pharmaceuticals4.2461 of 5 stars$38.39-1.8%$58.20+51.6%+73.0%$1.90B$336.89M-19.00140Upcoming EarningsNews CoveragePositive NewsTARSTarsus Pharmaceuticals2.0693 of 5 stars$48.51-1.5%$63.67+31.2%+65.2%$1.86B$182.95M-12.7350Earnings ReportUpcoming EarningsPositive NewsGMTXGemini TherapeuticsN/A$42.17+2.8%N/A+66.7%$1.83BN/A-42.1730BEAMBeam Therapeutics3.07 of 5 stars$18.24+7.3%$49.45+171.1%-6.1%$1.82B$63.52M-10.36510Upcoming EarningsShort Interest ↑High Trading VolumeNAMSNewAmsterdam Pharma3.1652 of 5 stars$16.26-0.5%$43.33+166.5%-12.3%$1.79B$45.56M-6.254Positive NewsKYMRKymera Therapeutics2.0027 of 5 stars$27.16+4.6%$56.36+107.5%+1.9%$1.76B$47.07M-11.61170News CoveragePositive NewsBLTEBelite Bio2.9736 of 5 stars$54.69-3.0%$96.67+76.8%+51.4%$1.74BN/A-49.2710News CoveragePositive News Related Companies and Tools Related Companies Metsera Competitors Schrödinger Competitors Denali Therapeutics Competitors Mirum Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Gemini Therapeutics Competitors Beam Therapeutics Competitors NewAmsterdam Pharma Competitors Kymera Therapeutics Competitors Belite Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMTX Stock Free IMTX Stock Alerts